Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVTX-009 in Moderate to Severe Hidradenitis Suppurativa
NCT06603077Phase 2Completed
- Sponsor
- Avalo Therapeutics
- Start
- Sep 2024
- Primary completion
- Feb 2026
- Modality
- Monoclonal Antibodies
- Countries
- 13
01
Overview
A Phase 2 trial of abdakibart in hidradenitis suppurativa (HS), sponsored by Avalo Therapeutics. Started Sep 2024; status: completed.
02
Drugs
abdakibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT06603077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06603077.